These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 19077160)

  • 41. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
    Stanulla M; Cario G; Meissner B; Schrauder A; Möricke A; Riehm H; Schrappe M
    Blood Cells Mol Dis; 2007; 39(2):160-3. PubMed ID: 17532236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004.
    Kamps WA; van der Pal-de Bruin KM; Veerman AJ; Fiocco M; Bierings M; Pieters R
    Leukemia; 2010 Feb; 24(2):309-19. PubMed ID: 20016528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference.
    Herold R; von Stackelberg A; Hartmann R; Eisenreich B; Henze G
    J Clin Oncol; 2004 Feb; 22(3):569-70; author reply 570-1. PubMed ID: 14752084
    [No Abstract]   [Full Text] [Related]  

  • 44. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.
    Barredo JC; Devidas M; Lauer SJ; Billett A; Marymont M; Pullen J; Camitta B; Winick N; Carroll W; Ritchey AK
    J Clin Oncol; 2006 Jul; 24(19):3142-9. PubMed ID: 16809737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group.
    Reismüller B; Peters C; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Dieckmann K; Gadner H; Attarbaschi A; Mann G;
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):e200-4. PubMed ID: 23652878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
    Kager L; Lion T; Attarbaschi A; Koenig M; Strehl S; Haas OA; Dworzak MN; Schrappe M; Gadner H; Mann G;
    Haematologica; 2007 Nov; 92(11):1561-4. PubMed ID: 18024406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors?
    Tzortzatou-Stathopoulou F; Moschovi MA; Papadopoulou AL; Barbounaki IG; Lambrou GI; Balafouta M; Syriopoulou V
    Eur J Haematol; 2005 Nov; 75(5):361-9. PubMed ID: 16191084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
    Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence.
    Wu S; Korte A; Gessner R; Henze G; Seeger K
    Cancer; 2003 Aug; 98(3):625-31. PubMed ID: 12879482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of acute lymphoblastic leukemia in children according to the ALL-BFM-90m protocol in the Russian Federation and the Republic of Belarus].
    Miakova NV; Aleĭnikova OV; Hartmann R; Rudneva AE; Trubina NM; Fechina LG; Timakov AM; Shamardina AV; Lebedev VV; Varfolomeeva SIu; Dudkin SD; Dyshlevaia ZM; Timofeeva VN; Rumiantsev AG; Henze H; Karachunskiĭ AI
    Vopr Onkol; 2002; 48(3):347-51. PubMed ID: 12455360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allogeneic BMT vs. chemotherapy in late bone marrow relapsed childhood non-T/non-B ALL: results of BFM ALL relapse studies. BFM Relapse Study Group.
    Schmid H; von Schenck U; Hartmann R; Borgmann A; Henze G
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():28-30. PubMed ID: 8932794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome of very late relapse in children with acute lymphoblastic leukemia.
    Rizzari C; Valsecchi MG; Aricò M; Miniero R; Messina C; De Rossi G; Testi AM; Mura R; Galimberti S; Biondi A; Locatelli F; Conter V
    Haematologica; 2004 Apr; 89(4):427-34. PubMed ID: 15075076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
    Schrappe M
    Radiat Prot Dosimetry; 2008; 132(2):130-3. PubMed ID: 19017727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.
    Meyr F; Escherich G; Mann G; Klingebiel T; Kulozik A; Rossig C; Schrappe M; Henze G; von Stackelberg A; Hitzler J
    Br J Haematol; 2013 Jul; 162(1):98-106. PubMed ID: 23594030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
    Gaynon PS; Harris RE; Altman AJ; Bostrom BC; Breneman JC; Hawks R; Steele D; Zipf T; Stram DO; Villaluna D; Trigg ME
    J Clin Oncol; 2006 Jul; 24(19):3150-6. PubMed ID: 16717292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
    Derwich K; Wachowiaki J; Kaczmarek-Kanoldi M; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Jackowska T; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Cwiklińska M; Kołtan A; Malinowska I; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A;
    Przegl Lek; 2006; 63(1):7-10. PubMed ID: 16892891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
    Creutzig U; Zimmermann M; Ritter J; Reinhardt D; Hermann J; Henze G; Jürgens H; Kabisch H; Reiter A; Riehm H; Gadner H; Schellong G
    Leukemia; 2005 Dec; 19(12):2030-42. PubMed ID: 16304570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.